spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  liposome 

 HSMN NewsFeed - 23 May 2022
Insmed Names Drayton Wise Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2021
GLOBAL Sarcoma Therapy Now Approved for Australian Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Dec 2020
Moebius Medical Announces FDA Clearance of IND Application for Phase IIb Clinical Trial of MM-II, a Novel Treatment for Knee Osteoarthritis Pain
Biopharmaceuticals Orthopaedic FDA
 HSMN NewsFeed - 24 Jul 2020
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 8 Jun 2020
Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Apr 2020
Insmed Appoints Carol A. Schafer to its Board of Directors
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 17 Feb 2020
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jan 2020
Insmed Appoints Sara Bonstein as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jan 2020
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 15 Nov 2019
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Nov 2019
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement for Octreotide Long Acting Injectable (LAI) Microsphere for Neuroendocrine Cancers and Acromegaly
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 19 Sep 2019
CASI Pharmaceuticals Announces the Promotion of Larry Zhang to President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Biopharmaceuticals Oncology Licensing Acquisitions
 HSMN NewsFeed - 3 Jun 2019
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Apr 2019
Aratana Therapeutics to be Acquired by Elanco Animal Health
Biopharmaceuticals Veterinary Mergers & Acquisitions
 HSMN NewsFeed - 9 Nov 2018
Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Aug 2018
Vyxeos(R) Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Jul 2018
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 22 Jun 2018
PharmaEngine Announces Positive Topline Results from Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Mar 2018
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Dec 2017
Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Apr 2017
Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Mar 2017
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Mar 2017
BLINCYTO(R) (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jan 2017
Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Jan 2017
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 28 Oct 2016
Alzheimer's Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jun 2016
Celator Pharmaceuticals(R) Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS(TM) (CPX-351) Significantly Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2016
Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 25 Apr 2016
Celator(R) Pharmaceuticals Announces Positive Results Demonstrating Reduced Healthcare Resource Use with VYXEOS(TM) Compared to Standard Treatment for Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Mar 2016
Merrimack Announces Inclusion of ONIVYDE(R) (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Nov 2015
Spectrum Pharmaceuticals Divests Rights to ZEVALIN(R) (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2015
Spectrum Pharmaceuticals Receives Complete Response Letter (CRL) from U.S. Food and Drug Administration (FDA) for EVOMELA(TM) (melphalan) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Oct 2015
Merrimack Announces U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2015
CASI Pharmaceuticals to Raise $25.1 Million in Private Placement of Common Stock and Warrants
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Aug 2015
Merrimack Pharmaceuticals Names Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development
Biopharmaceuticals Drug Delivery Oncology Personnel
 HSMN NewsFeed - 4 Mar 2015
CASI Pharmaceuticals Appoints Rong Chen, MD, Ph.D. As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Feb 2015
U.S. FDA Grants Priority Review for YONDELIS(R) (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Sep 2014
ProNAi Therapeutics, Inc. Names New President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 May 2014
Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2014
Spectrum Pharmaceuticals’ Pivotal Trial of Captisol-Enabled(TM) (Propylene Glycol-Free) Melphalan Meets Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Apr 2014
Merck Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2014
Celsion Announces FDA Clearance of the OPTIMA Study - A Pivotal Phase III Trial of ThermoDox in Primary Liver Cancer
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 6 Feb 2014
Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for Beleodaq(TM) (belinostat) for Injection, a novel pan-HDAC inhibitor
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Jan 2014
Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India
Biopharmaceuticals Distribution
 HSMN NewsFeed - 11 Nov 2013
InnoPharma Inc. Appoints Vish Shetty as Vice President, Business Development & Alliance Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Oct 2013
Pharmalink Receives US Orphan Drug Designation for Busulipo(TM), its Novel Oncology Product for Bone Marrow Transplantation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Oct 2013
MediciNova Appoints Geoffrey O'Brien as Vice President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 28 Aug 2013
Grifols and Aradigm Corporation Complete the Closing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin(R)
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 17 Jul 2013
Spectrum Pharmaceuticals Acquires Talon Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 May 2013
Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL in Femoral Nerve Block for Total Knee Arthroplasty
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2013
InnoPharma, Inc. Announces U.S. FDA Approval of Acetylcysteine Injection
Biopharmaceuticals Distribution FDA
 HSMN NewsFeed - 4 Jun 2012
Formula Pharmaceuticals Appoints Morton Collins to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 May 2012
Talon Therapeutics Appoints Head of Commercial Operations and Planning
Biopharmaceuticals Drug Delivery Oncology Personnel
 HSMN NewsFeed - 20 Jan 2012
Insmed Incorporated Provides Corporate Update
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2011
Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of EXPAREL(TM) For Postsurgical Pain Management
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Mar 2011
Celsion Receives European Orphan Drug Designation for ThermoDox(R) to Treat Primary Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Feb 2011
Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox(R) HEAT Study to Treat Primary Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jan 2011
Celator(R) Pharmaceuticals and Cephalon, Inc. Agree to Extend Research Agreement into Next Phase of Development
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Oct 2010
Celsion Receives Positive FDA Guidance for its New Drug Application for ThermoDox(R) to Treat Primary Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Sep 2010
Aradigm Presents Results Supporting Once-Daily Dosing With Its Inhaled Liposomal Ciprofloxacin Formulations at the 2010 European Respiratory Society (ERS) Annual Congress
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 1 Sep 2010
Celator(R) Pharmaceuticals Raises $20 Million in Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Aug 2010
Celsion Receives Fast Track Designation for ThermoDox(R) Development Program to Treat Primary Liver Cancer
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 29 Jun 2010
BIND Biosciences Appoints Ed Schnipper, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Mar 2010
Merck Serono: Erbitux Granted Extended Use in Japan for 1st-Line Treatment of mCRC Patients with KRAS Wild-Type Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Mar 2010
Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Feb 2010
Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Feb 2010
Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 7 Jan 2010
Sopherion Therapeutics Receives FDA Fast Track Designation for Myocet in Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Dec 2009
Hana Biosciences Announces Positive Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia at 51st American Society of Hematology Annual Meeting
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Nov 2009
MDRNA Expands RNAi Bladder Cancer Program With the Vancouver Prostate Centre
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Sep 2009
FDA Issues Complete Response Letter For Trabectedin Combined With DOXIL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jul 2009
Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jul 2009
Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jun 2009
Merck KGaA Initiates Phase III Study of Stimuvax in Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2009
Celsion Receives Final $15 Million Payment from Boston Scientific for Prolieve Assets Completing its Transition to a Drug Development Company
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Mar 2009
Celsion Receives Orphan Drug Designation for ThermoDox to Treat Primary Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Mar 2009
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jan 2009
Alnylam Provides Update on Kreutzer-Limmer Patent Family
Biopharmaceuticals
 HSMN NewsFeed - 12 Jan 2009
Hana Biosciences Appoints Thomas J. Tarlow as Vice President, Regulatory Affairs and Quality
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Oct 2008
Tracon Pharmaceuticals Appoints Bryan Leigh, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2008
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2008
Meda and Orexo in a Potential Billion SEK Deal
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 30 Mar 2008
Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Business Combination to Create Global Leader in RNAi Delivery and Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2008
Celsion Commences Global Phase III Study for Primary Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Feb 2008
Ireland Cancer Center and TRACON Pharmaceuticals Announce Treating the First Cancer Patient With TRC102, An Inhibitor of Chemotherapy Resistance
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Feb 2008
YM Biosciences USA Enrolls First Patient in Phase II Trial of Nimotuzumab in Children with Inoperable, Recurrent Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2007
BIND Biosciences, Inc. Closes $16M Series B Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Sep 2007
Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 27 Sep 2007
Celsion Bolsters Clinical Development Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Sep 2007
NEOPHARM Announces Management Appointment
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Sep 2007
Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 30 Aug 2007
YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Aug 2007
EKR Therapeutics Achieves Key Growth Milestone with the Acquisition of Rights from Pacira Pharmaceuticals to DepoDur(R), a Novel Extended-Release Opioid Analgesic for Post Operative Pain
Biopharmaceuticals Distribution
 HSMN NewsFeed - 15 Aug 2007
Oncoscience Ag, the European Partner of Ym Biosciences, Announces Completion of Patient Enrollment in Phase III Brain Cancer Trial of Nimotuzumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Aug 2007
BSD Medical Obtains Patent License for Primary Breast Cancer Treatment System from Duke University
Devices Licensing Oncology
 HSMN NewsFeed - 27 Jun 2007
YM BioSciences Receives FDA Clearance for an IND for its Fentanyl-Based Pain Product AeroLEF(TM)
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 21 Jun 2007
Celsion Completes Sale of Prolieve Assets
Devices Acquisitions Urology
 HSMN NewsFeed - 4 Jun 2007
YM BioSciences Cleared to Initiate Clinical trial of Nimotuzumab in Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
Intradigm Announces Addition of Samuel Zalipsky to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 May 2007
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 20 Apr 2007
FDA Grants Full Approval for DepoCyt(R) for the Treatment of Lymphomatous Meningitis
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 19 Apr 2007
NEOPHARM, Inc. Announces Strategic Reassessment and Reorganization
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Apr 2007
Celsion Announces Boston Scientific Exercises Its Option to Purchase Prolieve(R) Assets
Devices Urology Acquisitions
 HSMN NewsFeed - 16 Apr 2007
YM BioSciences' partner Daiichi Sankyo receives clearance for initial clinical trial in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Apr 2007
YM BioSciences Strengthens Program Management of Lead Drugs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Mar 2007
Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize D93, a Humanized Antibody for Cancer Treatment
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 Feb 2007
First patient enrolled in Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2007
YM BioSiences Announces Management Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Feb 2007
AGI Dermatics Presents Comparative Data That Indicates L-ergothioneine (EGT) Reduces UVA340-Induced Hydrogen Peroxide More Efficiently Than Idebenone
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
AGI Dermatics Data Shows Efficacy of Bicyclic Monoterpene Diols in Treatment of Molecular Markers of PhotoAged Skin
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 30 Jan 2007
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2007
Ortho Biotech Seeks FDA Approval for DOXIL(R) in Combination with VELCADE(R) to Treat Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jan 2007
Hana Biosciences Receives Orphan Drug Designation for Marqibo(R) (Vincristine Sulfate Liposomes Injection) for the Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Jan 2007
Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer now open for patient enrollment
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Dec 2006
Hana Biosciences Announces Filing of a Special Protocol Assessment (SPA) for Marqibo(R) (Vincristine Sulfate Liposomes Injection) in Relapsed Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Biomira receives special protocol assessment from the FDA for Phase III trial of Stimuvax for non-small cell lung cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Oct 2006
Biomira Announces Acquisition of ProlX Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Oct 2006
IDM Pharma Submits New Drug Application to the FDA for Junovan(TM) (mifamurtide) in the Treatment of Osteosarcoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Sep 2006
Celsion Obtains from Valentis Exclusive Rights to Pegylation Patents for use with Heat Activated Liposomes
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 7 Sep 2006
Celsion Announces Management Changes and Formation of Prolieve and Oncology Divisions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jun 2006
YM Biosciences announces independent Data Safety Monitoring Board recommends tesmilifene pivotal trial continue as planned
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 May 2006
Endovasc Announces Agreement with PYRAMID Labs to Manufacture Liprostin for Phase IIIa Trial
Biopharmaceuticals
 HSMN NewsFeed - 8 May 2006
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Biopharmaceuticals Oncology Licensing
Return to NewsFeed  

 Additional items found! 86

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 86 additional stories matching:
liposome
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.